Transfer lipopolysaccharide activates monocytes through TLR4, which is thought to increase the risk of cardiovascular disease in HIV-infected individuals.
About Me
CD BioGlyco is the world's leading independent biotechnology company, attracting a large number of researchers and partners, and has provided high-quality products and services for thousands of researchers worldwide.